Last updated: February 23, 2026
What are the specifics of the case?
Apple Inc. filed a patent infringement lawsuit against Masimo Corporation on April 20, 2022, in the U.S. District Court for the District of Delaware. The case number is 1:22-cv-01377. The complaint alleges that Masimo infringed multiple patents related to non-invasive measurement of blood properties, including pulse oximetry and related health monitoring technologies.
Claims:
- Patent Infringement: Apple asserts that Masimo’s products, particularly pulse oximeters and health monitoring devices, violate several of Apple’s patents, including U.S. Patent Nos. 10,904,756; 10,852,049; 10,843,152; 10,789,161; and 10,754,541.
- Patent Types: The patents cover innovations in sensor technology, data processing algorithms, and device design features used in health sensors.
Defendants:
- Masimo Corporation, based in Irvine, California.
- Masimo’s subsidiaries and affiliates.
Allegations:
- Apple claims that Masimo’s infringing devices are used in conjunction with Apple’s health ecosystems, including the Apple Watch and Apple HealthKit.
- The company seeks injunctive relief, damages, and attorneys' fees.
What is the current status of the case?
As of the latest update in February 2023:
- Initial pleadings are complete.
- Pending motions include Masimo’s motion to dismiss, filed in July 2022, challenging the patent validity and non-infringement allegations.
- Discovery phase has commenced, with both parties exchanging technical disclosures.
- Patent validity challenges: Masimo plans to invoke the inter partes review (IPR) process at the Patent Trial and Appeal Board (PTAB) to cancel specific patents asserted by Apple.
What are the key legal issues?
Patent validity and enforceability:
- Masimo challenges multiple patents' validity, citing lack of novelty and obviousness based on prior art references.
- Apple defends the patents, asserting they are novel, non-obvious, and properly issued.
Infringement:
- Apple contends that Masimo’s products infringe on several claims within its patents.
- Masimo maintains its products do not infringe and that the patents are invalid.
Patent strategy and market impact:
- The case fits into ongoing disputes between sensor technology providers and device manufacturers over health monitoring innovations.
- The outcome could affect the competitive landscape, particularly in non-invasive sensors embedded in consumer electronics and medical devices.
What are the potential legal and commercial implications?
Patent invalidity proceedings:
- Cancellation of patents via PTAB could weaken Apple’s case, leading to a possibility of invalidating key IP holdings.
- Success in validity challenges could enable Masimo to avoid infringement liabilities.
Judgments on damages and injunctions:
- A ruling in Apple’s favor could lead to substantial monetary damages and an injunction against Masimo’s infringing products.
- An adverse decision for Apple might open the market for Masimo’s devices, affecting Apple’s health monitoring revenue.
Anticipated timelines:
- Patent validity challenges via IPR are typically completed within 18 months to 2 years.
- Court rulings on infringement and damages may take longer, extending into 2024 or beyond.
Comparative context
| Aspect |
Apple Inc. v. Masimo |
Similar Cases |
| Filing date |
April 20, 2022 |
Fitbit Inc. v. Apple, 2020 |
| Patent focus |
Non-invasive blood measurement |
Wearable health sensors |
| Litigation phase |
Discovery, motions pending |
N/A |
| IPR involvement |
Planned by Masimo |
Common in patent disputes |
Conclusions based on current information
- The case underscores ongoing patent disputes in health sensor innovation and their impact on consumer and medical device markets.
- The outcome hinges on patent validity assessments and infringement findings, with potential for significant market implications.
Key Takeaways
- Apple alleges patent infringement by Masimo related to health monitoring sensors.
- The case involves challenges to patent validity, including potential IPR proceedings.
- The dispute exemplifies patent conflicts in non-invasive monitoring technology.
- Resolution timelines extend into 2024, with outcomes likely to influence market competition.
- The case highlights the strategic importance of patent rights in health-related consumer electronics.
FAQs
1. What patents are involved in the Apple vs. Masimo case?
Patents include U.S. Patent Nos. 10,904,756; 10,852,049; 10,843,152; 10,789,161; and 10,754,541, focusing on blood measurement and sensor technology.
2. What are Masimo’s defenses?
Masimo challenges the patents' validity, claims non-infringement, and plans to conduct IPR proceedings at the PTAB.
3. How might this case affect the market?
A ruling in Apple’s favor could restrict Masimo’s ability to sell certain devices, while a win for Masimo might allow continuation or expansion of its product lines.
4. When is a resolution expected?
Patent validity reviews via IPR could conclude within 18-24 months; court rulings on infringement could take longer, possibly into late 2024.
5. What precedent does this case set?
It highlights the ongoing importance of intellectual property rights in sensor technology and the strategic use of patent litigation to defend or challenge market positions.
References
[1] U.S. District Court for the District of Delaware. (2022). Apple Inc. v. Masimo Corporation, Complaint. Case No. 1:22-cv-01377.
